Transcutaneous Electrical Acupoint Stimulation on Symptoms Associated with Chemotherapy Induced Peripheral Neuropathy

Summary

Breast cancer ranks first in Taiwan's top ten gynecological cancers. Chemotherapy is a standard treatment method for colorectal cancer and breast cancer, but while destroying cancer cells, it also destroys healthy cells, resulting in side effects. Peripheral neuropathy can lead to peripheral nerve damage and decreased activity, which affects the patient's quality of life. Currently, there is no standard and effective method for treating peripheral neuropathy caused by chemotherapy. Therefore, the purpose of this study is to investigate the effect of percutaneous electrical acupoint stimulation on improving peripheral nerve symptoms in breast cancer patients undergoing chemotherapy.

Eligibility

Inclusion Criteria:

1. Primary diagnosed with breast cancer for the first time by a physician.
2. Patients who have completed chemotherapy or postoperative adjuvant chemotherapy within 3 months, and the chemotherapy drugs used are paclitaxel, vinblastine or platinum drugs.
3. Patients who have been evaluated by doctors as peripheral neuropathy caused by chemotherapy, and whose symptoms persist after completing chemotherapy.
4. Peripheral sensory or peripheral motor neuropathy grade ≥ 2 in general toxicity criteria (NCI-CTCAE).
5. Those who have clear consciousness and can communicate in Mandarin or Taiwanese.

Exclusion Criteria:

1. Patients suffering from carcinoma in situ.
2. Patients suffering from stage IV cancer.
3. Patients suffering from metastatic cancer.
4. Patients receiving peripheral neuropathy drugs (Duloxetine)
5. Patients receiving acupoint stimulation therapy.
6. Patients who are allergic to silicone patches.
7. Patients with cardiac pacemakers.
8. Patients suffering from diabetic peripheral neuropathy.
9. Patients suffering from peripheral neuropathy of acquired immunodeficiency syndrome.
10. Patients receiving treatment for mental illness.

Conditions4

Browse More Trials